Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib in Combination With Radiation and Adjuvant Temozolomide in Glioblastoma
NCT04555577Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of peposertib in glioblastoma (GBM) and Gliosarcoma (GS) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 10 weeks and Ability of Peposertib to cross the blood brain barrier at 4 hours. Started Sep 2020; status: active, not recruiting.
02
Drugs
peposertib
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT04555577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555577.